Key result
Intra-arterial biologics during thrombectomy may promote neuroregeneration and limit neuronal death in ischemic stroke.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Ischemic stroke is becoming a primary cause of disability and death worldwide. To date, therapeutic options remain limited focusing on mechanical thrombolysis or administration of thrombolytic agents. However, these therapies do not promote neuroprotection and neuro-restoration of the ischemic area of the brain. AREAS COVERED: This review highlights the option of minimal invasive, intra-arterial, administration of biological agents for stroke therapy. The authors provide an update of all available studies, discuss issues that influence outcomes and describe future perspectives which aim to improve clinical outcomes. New therapeutic options based on cellular and molecular interactions following an ischemic brain event, will be highlighted. EXPERT OPINION: Intra-arterial administration of biological agents during trans-catheter thrombolysis or thrombectomy could limit neuronal cell death and facilitate regeneration or neurogenesis following ischemic brain injury. Despite the initial progress, further meticulous studies are needed in order to establish the clinical use of stem cell-induced neuroprotection and neuroregeneration.
No takes yet. Share an insight, caveat, or question.
Spiliοpoulos et al. (2019) conducted a review in Ischemic stroke. Intra-arterial administration of cell-based biological agents was evaluated. Intra-arterial biological agents during thrombectomy may limit neuronal death and promote neuroregeneration after ischemic stroke, though further studies are needed.
Synapse has enriched 10 related papers. Consider them for comparative context: